Cargando…

Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis

BACKGROUND: Chronic hepatitis B liver fibrosis is significant public concern. Ganshuang granules (GSG) are used to treat liver fibrosis for a long time. The aim of this study is to synthesize related data to explore efficacy and safety of GSG as an adjuvant treatment for chronic hepatitis B liver fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Shaoqian, Liu, Yefang, Jiang, Cen, Li, Baixue, Wen, Li, Feng, Quansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544267/
https://www.ncbi.nlm.nih.gov/pubmed/33031339
http://dx.doi.org/10.1097/MD.0000000000022692
_version_ 1783591824385900544
author Zeng, Shaoqian
Liu, Yefang
Jiang, Cen
Li, Baixue
Wen, Li
Feng, Quansheng
author_facet Zeng, Shaoqian
Liu, Yefang
Jiang, Cen
Li, Baixue
Wen, Li
Feng, Quansheng
author_sort Zeng, Shaoqian
collection PubMed
description BACKGROUND: Chronic hepatitis B liver fibrosis is significant public concern. Ganshuang granules (GSG) are used to treat liver fibrosis for a long time. The aim of this study is to synthesize related data to explore efficacy and safety of GSG as an adjuvant treatment for chronic hepatitis B liver fibrosis. METHODS: Electronic database were used to identify related studies. We chose PubMed, China Knowledge Network Infrastructure, China Biomedical Database, Wan Fang Data, VIP Database, EMBASE, and Cochrane Library as retrieval tool. Two independent individuals conducted the publication selection, data extraction, data assessment. Any problems between 2 researchers will be resolved by a third reviewer through negotiation. RevMan 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) software will be used for data analysis. RESULTS: This study will systematically detect the efficacy and safety of GSG for treating chronic hepatitis B liver fibrosis. CONCLUSION: This study will provide scientific evidence to explorer whether GSG are efficacy and safety in treating chronic hepatitis B liver fibrosis. PROSPERO REGISTRATION NUMBER: INPLASY202090027
format Online
Article
Text
id pubmed-7544267
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75442672020-10-30 Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis Zeng, Shaoqian Liu, Yefang Jiang, Cen Li, Baixue Wen, Li Feng, Quansheng Medicine (Baltimore) 3700 BACKGROUND: Chronic hepatitis B liver fibrosis is significant public concern. Ganshuang granules (GSG) are used to treat liver fibrosis for a long time. The aim of this study is to synthesize related data to explore efficacy and safety of GSG as an adjuvant treatment for chronic hepatitis B liver fibrosis. METHODS: Electronic database were used to identify related studies. We chose PubMed, China Knowledge Network Infrastructure, China Biomedical Database, Wan Fang Data, VIP Database, EMBASE, and Cochrane Library as retrieval tool. Two independent individuals conducted the publication selection, data extraction, data assessment. Any problems between 2 researchers will be resolved by a third reviewer through negotiation. RevMan 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) software will be used for data analysis. RESULTS: This study will systematically detect the efficacy and safety of GSG for treating chronic hepatitis B liver fibrosis. CONCLUSION: This study will provide scientific evidence to explorer whether GSG are efficacy and safety in treating chronic hepatitis B liver fibrosis. PROSPERO REGISTRATION NUMBER: INPLASY202090027 Lippincott Williams & Wilkins 2020-10-09 /pmc/articles/PMC7544267/ /pubmed/33031339 http://dx.doi.org/10.1097/MD.0000000000022692 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 3700
Zeng, Shaoqian
Liu, Yefang
Jiang, Cen
Li, Baixue
Wen, Li
Feng, Quansheng
Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis
title Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis
title_full Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis
title_fullStr Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis
title_full_unstemmed Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis
title_short Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis
title_sort clinical efficacy and safety of ganshuang granules as an adjuvant treatment for chronic hepatitis b liver fibrosis: a protocol for systematic review and meta analysis
topic 3700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544267/
https://www.ncbi.nlm.nih.gov/pubmed/33031339
http://dx.doi.org/10.1097/MD.0000000000022692
work_keys_str_mv AT zengshaoqian clinicalefficacyandsafetyofganshuanggranulesasanadjuvanttreatmentforchronichepatitisbliverfibrosisaprotocolforsystematicreviewandmetaanalysis
AT liuyefang clinicalefficacyandsafetyofganshuanggranulesasanadjuvanttreatmentforchronichepatitisbliverfibrosisaprotocolforsystematicreviewandmetaanalysis
AT jiangcen clinicalefficacyandsafetyofganshuanggranulesasanadjuvanttreatmentforchronichepatitisbliverfibrosisaprotocolforsystematicreviewandmetaanalysis
AT libaixue clinicalefficacyandsafetyofganshuanggranulesasanadjuvanttreatmentforchronichepatitisbliverfibrosisaprotocolforsystematicreviewandmetaanalysis
AT wenli clinicalefficacyandsafetyofganshuanggranulesasanadjuvanttreatmentforchronichepatitisbliverfibrosisaprotocolforsystematicreviewandmetaanalysis
AT fengquansheng clinicalefficacyandsafetyofganshuanggranulesasanadjuvanttreatmentforchronichepatitisbliverfibrosisaprotocolforsystematicreviewandmetaanalysis